Emmaus Medical Announces Completion of Enrollment for its Phase 3 Sickle Cell Disease TrialDecember 03, 2012 Read More
Emmaus CEO Yutaka Niihara, M.D., Issues Statement In Connection with Status of Company’s Phase III FDA Sickle Cell Treatment TrialsNovember 22, 2012 Read More
Emmaus Life Sciences Issues Statement In Response to Announcement by AFH Holding & AdvisoryOctober 10, 2012 Emmaus Life Sciences, Inc., a specialty pharmaceutical and regenerative medicine company, today issued the following statement in response to an announcement issued October 9, 2012, by AFH Holding & Advisory, LLC. Read More